Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 5, 2012, Pages 493-497

  Schmidinger, Manuela ^a   Szczylik, Cezary ^b   Sternberg, Cora N ^c   Kania, Marek ^d   Kelly, Claudia Sue ^d   Decker, Rodney ^d   Hamid, Oday ^d   Faelker, Taron ^e   Escudier, Bernard ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d ELI LILLY AND COMPANY   (United States)

^e i3 Statprobe   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

enzastaurin; renal cell carcinoma; sunitinib

Indexed keywords

ENZASTAURIN; PLACEBO; SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL OBSTRUCTION; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY CARCINOMA; LEUKOPENIA; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ULCER; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; INTERNATIONAL AGENCIES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRROLES; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84866742044     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31821cfc41     Document Type: Article

References (18)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
2. National Cancer Institute. Kidney cancer. Available from: http://www.cancer.gov/cancertopics/types/kidney. Accessed August 25, 2010.
3. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006;94:614-619.
4. Linehan WM, Shipley WU, Parkinson DR. Cancer of the kidney and ureter. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers;1997:1271-1297.
5. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
6. Kish JA, Wolf M, Crawford ED, et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma: a Southwest Oncology Group Study. Cancer. 1994;74:916-919.
7. Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1993;4:331-332.
8. Furge KA, MacKeigan JP, Teh BT. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol. 2010;11:571-578.
9. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-896.
10. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
11. Li J, Gobe G. Protein kinase C activation and its role in kidney disease. Nephrology (Carlton). 2006;11:428-434.
12. Kreisl TN, Kim L, Moore K, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009;15: 3617-3623.
13. Kreisl T, Kotliarova S, Butman J, et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncology. 2010;12:181-189.
14. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24:4092-4099.
15. Vogl UM, Berger W, Micksche M, et al. Synergistic effect of sorafenib and sunitinib with enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett. 2009;277:218-226. [Epub 2009 Jan 25].
16. National Cancer Institute: Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, version 3.0. August 9, 2006. Available at http://ctep.cancer.gov/protocol Development/electronic-applications/docs/ ctcaev3.pdf. Accessed November 16, 2010.
17. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257-2267.
18. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61:515-524. [Epub 2007 May 16].